GlassScriptPhysician profile
Jeffrey Ray Williams
NPI 1972098614
$935.82
in general payments reported to CMS, 2019-2025
22 companies · $224 in 2025
The $224 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $45.57 · 2023: $279 · 2024: $387 · 2025: $224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $890.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $890.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $114.96 | 2023-2025 | Rexulti |
| Glaxosmithkline, LLC. | $84.62 | 2023-2025 | Shingrix, Arexvy, Bexsero |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.98 | 2022-2025 | Jardiance, Ofev |
| Abbott Laboratories | $75.25 | 2024-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $70.33 | 2024 | Wegovy, Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $59.13 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $52.19 | 2023 | Verquvo, Belsomra, Steglatro |
| Astrazeneca Pharmaceuticals LP | $50.11 | 2024 | Farxiga, Airsupra |
| Phathom Pharmaceuticals, INC. | $49.44 | 2024 | Voquezna |
| Boston Scientific Corporation | $43.40 | 2025 | General - Pain Management |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.63 | 2025 | Caplyta |
| Lilly USA, LLC | $32.84 | 2023-2024 | Zepbound, Jardiance |
| Abbvie INC. | $26.72 | 2023 | Ubrelvy, Qulipta |
| Sumitomo Pharma America, INC. | $26.55 | 2023-2025 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $23.14 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $17.47 | 2023 | Accrufer |
| Idorsia Pharmaceuticals US INC | $16.60 | 2022 | |
| Sanofi Pasteur INC. | $16.31 | 2023 | |
| Dexcom, INC. | $16.27 | 2024 | Dexcom G6 Transmitter |
| Amgen INC. | $14.55 | 2024 | Repatha, Otezla |
| Sunovion Pharmaceuticals INC. | $14.39 | 2022 | |
| Exact Sciences Corporation | $13.94 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.